- Conditions
- Major Depressive Disorder
- Interventions
- Pregnenolone 500 mg, Pregnenolone 800 mg, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 8,461
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
- Interventions
- Midostaurin
- Drug
- Lead sponsor
- Jason Robert Gotlib
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 3
- States / cities
- Stanford, California • Boston, Massachusetts • St Louis, Missouri
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 48
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more
- Conditions
- Friedreich's Ataxia
- Interventions
- Low dose cohort, High dose cohort
- Drug
- Lead sponsor
- Biojiva LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Long Beach, California • Tampa, Florida
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- Epcoritamab, Rituximab, Lenalidomide
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 25 more
- Conditions
- ADHD
- Interventions
- Placebo, 400mg SPN-812, 600mg SPN-812
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 14
- States / cities
- Long Beach, California • Colorado Springs, Colorado • Bradenton, Florida + 9 more
- Conditions
- Syphilis, Human Immunodeficiency Virus
- Interventions
- Cefixime 400mg, benzathine penicillin
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Insufficiency, Pancreatic Cancer, Pancreatic Enzyme Abnormality
- Interventions
- Pancrelipase, Placebo Oral Capsule
- Drug
- Lead sponsor
- Massimo Raimondo, M.D.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Treatment Resistant Depression, Inflammation, Overweight
- Interventions
- Omega 3, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah
- Conditions
- Influenza, Human
- Interventions
- Oseltamivir, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 44
- States / cities
- Chandler, Arizona • Costa Mesa, California • Garden Grove, California + 37 more
- Conditions
- Advanced Hematological Disorders
- Interventions
- ORH-2014
- Drug
- Lead sponsor
- Orsenix LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- New York, New York • Nashville, Tennessee • Houston, Texas
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- Cipaglucosidase Alfa, Miglustat
- Biological · Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 6 more
- Conditions
- Colonoscopy Preparation
- Interventions
- PEG-ELS current standard of care, PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Novi, Michigan • Southfield, Michigan • Warren, Michigan
- Conditions
- Ulcerative Colitis
- Interventions
- Balsalazide
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SHP465
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Orlando, Florida • Evansville, Indiana + 5 more
- Conditions
- Hypercholesterolemia
- Interventions
- MK-0616
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Advanced Solid Tumor
- Interventions
- STP1002
- Drug
- Lead sponsor
- ST Pharm Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Denver, Colorado • Evanston, Illinois
- Conditions
- Cushings Disease, Cushing Disease
- Interventions
- LCI699
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 1 more
- Conditions
- Covid19
- Interventions
- TQ Formula/Tab
- Drug
- Lead sponsor
- Novatek Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- San Diego, California • Hialeah, Florida • Houston, Texas
- Conditions
- Cognitive Impairments, RRSO
- Interventions
- lisdexamfetamine, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 30 Years to 60 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Epilepsy
- Interventions
- lamotrigine, atorvastatin, phenytoin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Fragile X Syndrome
- Interventions
- Gaboxadol, Placebo
- Drug
- Lead sponsor
- Craig Erickson
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Alcohol-induced Cue-craving, Alcohol Sensitivity
- Interventions
- Placebo Comparator, Active Comparator: Atomoxetine, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Charlottesville/ Richmond, Virginia
- Conditions
- Healthy Participants
- Interventions
- Rosuvastatin, BPN14770
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas